Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

The SMALL Trial: A Big Change for Small Breast Cancers.

Morgan J, Potter S, Sharma N, McIntosh SA; SMALL Trial Management Group, Coles CE, Dodwell D, Elder K, Gaunt C, Lyburn ID, McIntosh SA, Morgan J, Paramasivan S, Pinder S, Pirrie S, Potter S, Rea D, Roberts T, Sharma N, Stobart H, Taylor-Phillips S, Wallis M, Wilcox M.

Clin Oncol (R Coll Radiol). 2019 May 31. pii: S0936-6555(19)30200-6. doi: 10.1016/j.clon.2019.05.008. [Epub ahead of print] No abstract available.

PMID:
31160130
2.

Understanding the BIG results: Insights from the BIG 1-98 trial analyses.

Wardley AM.

Adv Ther. 2008 Dec;25(12):1257-75. doi: 10.1007/s12325-008-0128-5. Review.

PMID:
19096768
3.

Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98.

Kensler KH, Regan MM, Heng YJ, Baker GM, Pyle ME, Schnitt SJ, Hazra A, Kammler R, Thürlimann B, Colleoni M, Viale G, Brown M, Tamimi RM.

Breast Cancer Res. 2019 Feb 22;21(1):30. doi: 10.1186/s13058-019-1118-z.

4.

The impact of personalized medicine on survival: comparisons of results in metastatic breast, colorectal and non-small-cell lung cancers.

Rossi A, Torri V, Garassino MC, Porcu L, Galetta D.

Cancer Treat Rev. 2014 May;40(4):485-94. doi: 10.1016/j.ctrv.2013.09.012. Epub 2013 Sep 25. Review.

PMID:
24112813
5.

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.

Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fernö M, Rydén L, Mouridsen H; Danish Breast Cancer Cooperative Group.

Breast Cancer Res Treat. 2017 Nov;166(2):481-490. doi: 10.1007/s10549-017-4416-0. Epub 2017 Aug 1.

6.

Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG).

Lancet Oncol. 2011 Nov;12(12):1101-8. doi: 10.1016/S1470-2045(11)70270-4. Epub 2011 Oct 20.

7.

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.

Monnier AM.

Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.

PMID:
17492927
8.

[Therapy and prognosis of small breast cancers. Comparison of subcutaneous mastectomy procedures with ablatio mammae].

Kieback DG, Beller FK, Nitsch CD, Krieg V, Nienhaus H, Niedner WE.

Geburtshilfe Frauenheilkd. 1990 Oct;50(10):754-70. German. Erratum in: Geburtshilfe Frauenheilkd 1990 Dec;50(12):994.

PMID:
2286314
9.

Serum big endothelin-1 levels in female patients with breast cancer.

Yildirim Y, Gunel N, Coskun U, Sancak B, Bukan N, Aslan S, Cetin A.

Int Immunopharmacol. 2008 Aug;8(8):1119-23. doi: 10.1016/j.intimp.2008.03.023. Epub 2008 Apr 28.

PMID:
18550016
10.

Dual time point FDG-PET/CT imaging... Potential tool for diagnosis of breast cancer.

Zytoon AA, Murakami K, El-Kholy MR, El-Shorbagy E.

Clin Radiol. 2008 Nov;63(11):1213-27. doi: 10.1016/j.crad.2008.03.014. Epub 2008 Sep 14.

PMID:
18929039
11.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.

PMID:
18083065
12.

Update of the BIG 1-98 Trial: where do we stand?

Joerger M, Thürlimann B.

Breast. 2009 Oct;18 Suppl 3:S78-82. doi: 10.1016/S0960-9776(09)70278-4.

PMID:
19914548
13.

Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.

Regan MM, Price KN, Giobbie-Hurder A, Thürlimann B, Gelber RD; International Breast Cancer Study Group and BIG 1-98 Collaborative Group.

Breast Cancer Res. 2011 May 26;13(3):209. doi: 10.1186/bcr2837. Review.

14.

Interventions for treating osteoarthritis of the big toe joint.

Zammit GV, Menz HB, Munteanu SE, Landorf KB, Gilheany MF.

Cochrane Database Syst Rev. 2010 Sep 8;(9):CD007809. doi: 10.1002/14651858.CD007809.pub2. Review.

PMID:
20824867
15.

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM.

Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047.

PMID:
30753274
16.

Performance of breast cancer screening using digital breast tomosynthesis: results from the prospective population-based Oslo Tomosynthesis Screening Trial.

Skaane P, Sebuødegård S, Bandos AI, Gur D, Østerås BH, Gullien R, Hofvind S.

Breast Cancer Res Treat. 2018 Jun;169(3):489-496. doi: 10.1007/s10549-018-4705-2. Epub 2018 Feb 10.

PMID:
29429017
17.

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.

Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T, Wilking N.

J Natl Cancer Inst. 1995 May 3;87(9):645-51.

PMID:
7752269
18.

HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2.

Bartlett JMS, Ahmed I, Regan MM, Sestak I, Mallon EA, Dell'Orto P, Thürlimann B, Seynaeve C, Putter H, Van de Velde CJH, Brookes CL, Forbes JF, Viale G, Cuzick J, Dowsett M, Rea DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG).

Eur J Cancer. 2017 Jul;79:129-138. doi: 10.1016/j.ejca.2017.03.033. Epub 2017 May 8.

PMID:
28494403
19.

Reducing Racial Disparities in Breast Cancer Care: The Role of 'Big Data'.

Reeder-Hayes KE, Troester MA, Meyer AM.

Oncology (Williston Park). 2017 Oct 15;31(10):756-62. Review.

20.

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A.

J Clin Oncol. 2008 Apr 20;26(12):1972-9. doi: 10.1200/JCO.2007.14.0459. Epub 2008 Mar 10.

PMID:
18332471

Supplemental Content

Support Center